nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP2C18—Ifosfamide—testicular cancer	0.148	0.178	CbGbCtD
Buprenorphine—CYP2A6—Ifosfamide—testicular cancer	0.0718	0.0866	CbGbCtD
Buprenorphine—ABCG2—Dactinomycin—testicular cancer	0.0563	0.0679	CbGbCtD
Buprenorphine—CYP3A7—Ifosfamide—testicular cancer	0.0491	0.0592	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Ifosfamide—testicular cancer	0.0491	0.0592	CbGbCtD
Buprenorphine—ABCG2—Carboplatin—testicular cancer	0.0378	0.0456	CbGbCtD
Buprenorphine—CYP3A5—Ifosfamide—testicular cancer	0.0368	0.0444	CbGbCtD
Buprenorphine—CYP2C8—Ifosfamide—testicular cancer	0.0354	0.0427	CbGbCtD
Buprenorphine—ABCG2—Cisplatin—testicular cancer	0.0323	0.039	CbGbCtD
Buprenorphine—ABCG2—Etoposide—testicular cancer	0.0318	0.0383	CbGbCtD
Buprenorphine—CYP2C19—Ifosfamide—testicular cancer	0.0297	0.0358	CbGbCtD
Buprenorphine—CYP2C9—Ifosfamide—testicular cancer	0.0247	0.0298	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—testicular cancer	0.0217	0.0261	CbGbCtD
Buprenorphine—ABCG2—Methotrexate—testicular cancer	0.021	0.0253	CbGbCtD
Buprenorphine—ABCB1—Dactinomycin—testicular cancer	0.0203	0.0245	CbGbCtD
Buprenorphine—CYP3A5—Etoposide—testicular cancer	0.0176	0.0212	CbGbCtD
Buprenorphine—CYP2C8—Etoposide—testicular cancer	0.0169	0.0204	CbGbCtD
Buprenorphine—CYP3A4—Ifosfamide—testicular cancer	0.0144	0.0173	CbGbCtD
Buprenorphine—CYP1A2—Etoposide—testicular cancer	0.0131	0.0158	CbGbCtD
Buprenorphine—ABCB1—Vinblastine—testicular cancer	0.0127	0.0153	CbGbCtD
Buprenorphine—CYP2C9—Cisplatin—testicular cancer	0.012	0.0145	CbGbCtD
Buprenorphine—CYP2D6—Vinblastine—testicular cancer	0.012	0.0145	CbGbCtD
Buprenorphine—ABCB1—Cisplatin—testicular cancer	0.0117	0.0141	CbGbCtD
Buprenorphine—ABCB1—Etoposide—testicular cancer	0.0115	0.0138	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—testicular cancer	0.00781	0.00942	CbGbCtD
Buprenorphine—CYP3A4—Vinblastine—testicular cancer	0.00762	0.00919	CbGbCtD
Buprenorphine—ABCB1—Methotrexate—testicular cancer	0.00757	0.00913	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—testicular cancer	0.00736	0.00888	CbGbCtD
Buprenorphine—CYP3A4—Etoposide—testicular cancer	0.00686	0.00828	CbGbCtD
Buprenorphine—CYP3A4—Doxorubicin—testicular cancer	0.00468	0.00565	CbGbCtD
Buprenorphine—Infestation NOS—Doxorubicin—testicular cancer	0.000161	0.00094	CcSEcCtD
Buprenorphine—Infestation—Doxorubicin—testicular cancer	0.000161	0.00094	CcSEcCtD
Buprenorphine—Visual impairment—Methotrexate—testicular cancer	0.000161	0.000939	CcSEcCtD
Buprenorphine—Vomiting—Ifosfamide—testicular cancer	0.000159	0.00093	CcSEcCtD
Buprenorphine—Hypersensitivity—Cisplatin—testicular cancer	0.000159	0.000929	CcSEcCtD
Buprenorphine—Bradycardia—Epirubicin—testicular cancer	0.000159	0.000928	CcSEcCtD
Buprenorphine—Rash—Ifosfamide—testicular cancer	0.000158	0.000923	CcSEcCtD
Buprenorphine—Dermatitis—Ifosfamide—testicular cancer	0.000158	0.000922	CcSEcCtD
Buprenorphine—Urticaria—Etoposide—testicular cancer	0.000157	0.000918	CcSEcCtD
Buprenorphine—Rhinitis—Epirubicin—testicular cancer	0.000156	0.000914	CcSEcCtD
Buprenorphine—Abdominal pain—Etoposide—testicular cancer	0.000156	0.000914	CcSEcCtD
Buprenorphine—Body temperature increased—Etoposide—testicular cancer	0.000156	0.000914	CcSEcCtD
Buprenorphine—Conjunctivitis—Doxorubicin—testicular cancer	0.000156	0.000914	CcSEcCtD
Buprenorphine—Urinary tract infection—Doxorubicin—testicular cancer	0.000156	0.000914	CcSEcCtD
Buprenorphine—Eye disorder—Methotrexate—testicular cancer	0.000156	0.000911	CcSEcCtD
Buprenorphine—Tinnitus—Methotrexate—testicular cancer	0.000155	0.000908	CcSEcCtD
Buprenorphine—Hypoaesthesia—Epirubicin—testicular cancer	0.000155	0.000907	CcSEcCtD
Buprenorphine—Asthenia—Cisplatin—testicular cancer	0.000155	0.000905	CcSEcCtD
Buprenorphine—Pharyngitis—Epirubicin—testicular cancer	0.000155	0.000905	CcSEcCtD
Buprenorphine—Cardiac disorder—Methotrexate—testicular cancer	0.000155	0.000904	CcSEcCtD
Buprenorphine—Sweating—Doxorubicin—testicular cancer	0.000154	0.000901	CcSEcCtD
Buprenorphine—Urinary tract disorder—Epirubicin—testicular cancer	0.000154	0.000901	CcSEcCtD
Buprenorphine—Oedema peripheral—Epirubicin—testicular cancer	0.000154	0.000898	CcSEcCtD
Buprenorphine—Connective tissue disorder—Epirubicin—testicular cancer	0.000153	0.000896	CcSEcCtD
Buprenorphine—Urethral disorder—Epirubicin—testicular cancer	0.000153	0.000894	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000152	0.000889	CcSEcCtD
Buprenorphine—Angiopathy—Methotrexate—testicular cancer	0.000151	0.000884	CcSEcCtD
Buprenorphine—Sinusitis—Doxorubicin—testicular cancer	0.000151	0.000882	CcSEcCtD
Buprenorphine—Immune system disorder—Methotrexate—testicular cancer	0.00015	0.00088	CcSEcCtD
Buprenorphine—Visual impairment—Epirubicin—testicular cancer	0.00015	0.000879	CcSEcCtD
Buprenorphine—Mediastinal disorder—Methotrexate—testicular cancer	0.00015	0.000878	CcSEcCtD
Buprenorphine—Chills—Methotrexate—testicular cancer	0.000149	0.000874	CcSEcCtD
Buprenorphine—Nausea—Ifosfamide—testicular cancer	0.000149	0.000869	CcSEcCtD
Buprenorphine—Diarrhoea—Cisplatin—testicular cancer	0.000148	0.000863	CcSEcCtD
Buprenorphine—Bradycardia—Doxorubicin—testicular cancer	0.000147	0.000859	CcSEcCtD
Buprenorphine—Mental disorder—Methotrexate—testicular cancer	0.000146	0.000854	CcSEcCtD
Buprenorphine—Eye disorder—Epirubicin—testicular cancer	0.000146	0.000852	CcSEcCtD
Buprenorphine—Hypersensitivity—Etoposide—testicular cancer	0.000146	0.000851	CcSEcCtD
Buprenorphine—Tinnitus—Epirubicin—testicular cancer	0.000145	0.00085	CcSEcCtD
Buprenorphine—Erythema—Methotrexate—testicular cancer	0.000145	0.000848	CcSEcCtD
Buprenorphine—Malnutrition—Methotrexate—testicular cancer	0.000145	0.000848	CcSEcCtD
Buprenorphine—Flushing—Epirubicin—testicular cancer	0.000145	0.000846	CcSEcCtD
Buprenorphine—Cardiac disorder—Epirubicin—testicular cancer	0.000145	0.000846	CcSEcCtD
Buprenorphine—Rhinitis—Doxorubicin—testicular cancer	0.000145	0.000846	CcSEcCtD
Buprenorphine—Hypoaesthesia—Doxorubicin—testicular cancer	0.000144	0.000839	CcSEcCtD
Buprenorphine—Pharyngitis—Doxorubicin—testicular cancer	0.000143	0.000837	CcSEcCtD
Buprenorphine—Urinary tract disorder—Doxorubicin—testicular cancer	0.000142	0.000833	CcSEcCtD
Buprenorphine—Oedema peripheral—Doxorubicin—testicular cancer	0.000142	0.000831	CcSEcCtD
Buprenorphine—Dysgeusia—Methotrexate—testicular cancer	0.000142	0.000831	CcSEcCtD
Buprenorphine—Asthenia—Etoposide—testicular cancer	0.000142	0.000829	CcSEcCtD
Buprenorphine—Connective tissue disorder—Doxorubicin—testicular cancer	0.000142	0.000829	CcSEcCtD
Buprenorphine—Angiopathy—Epirubicin—testicular cancer	0.000141	0.000827	CcSEcCtD
Buprenorphine—Urethral disorder—Doxorubicin—testicular cancer	0.000141	0.000827	CcSEcCtD
Buprenorphine—Immune system disorder—Epirubicin—testicular cancer	0.000141	0.000824	CcSEcCtD
Buprenorphine—Mediastinal disorder—Epirubicin—testicular cancer	0.00014	0.000822	CcSEcCtD
Buprenorphine—Back pain—Methotrexate—testicular cancer	0.00014	0.00082	CcSEcCtD
Buprenorphine—Chills—Epirubicin—testicular cancer	0.00014	0.000818	CcSEcCtD
Buprenorphine—Pruritus—Etoposide—testicular cancer	0.00014	0.000818	CcSEcCtD
Buprenorphine—Visual impairment—Doxorubicin—testicular cancer	0.000139	0.000813	CcSEcCtD
Buprenorphine—Vomiting—Cisplatin—testicular cancer	0.000137	0.000802	CcSEcCtD
Buprenorphine—Vision blurred—Methotrexate—testicular cancer	0.000137	0.000799	CcSEcCtD
Buprenorphine—Mental disorder—Epirubicin—testicular cancer	0.000137	0.000799	CcSEcCtD
Buprenorphine—Rash—Cisplatin—testicular cancer	0.000136	0.000795	CcSEcCtD
Buprenorphine—Dermatitis—Cisplatin—testicular cancer	0.000136	0.000795	CcSEcCtD
Buprenorphine—Erythema—Epirubicin—testicular cancer	0.000136	0.000794	CcSEcCtD
Buprenorphine—Malnutrition—Epirubicin—testicular cancer	0.000136	0.000794	CcSEcCtD
Buprenorphine—Diarrhoea—Etoposide—testicular cancer	0.000135	0.000791	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—testicular cancer	0.000135	0.000788	CcSEcCtD
Buprenorphine—Ill-defined disorder—Methotrexate—testicular cancer	0.000135	0.000787	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—testicular cancer	0.000134	0.000787	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—testicular cancer	0.000134	0.000783	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—testicular cancer	0.000134	0.000783	CcSEcCtD
Buprenorphine—Flatulence—Epirubicin—testicular cancer	0.000134	0.000782	CcSEcCtD
Buprenorphine—Tension—Epirubicin—testicular cancer	0.000133	0.000779	CcSEcCtD
Buprenorphine—Dysgeusia—Epirubicin—testicular cancer	0.000133	0.000777	CcSEcCtD
Buprenorphine—Nervousness—Epirubicin—testicular cancer	0.000132	0.000771	CcSEcCtD
Buprenorphine—Back pain—Epirubicin—testicular cancer	0.000131	0.000768	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—testicular cancer	0.000131	0.000765	CcSEcCtD
Buprenorphine—Malaise—Methotrexate—testicular cancer	0.000131	0.000765	CcSEcCtD
Buprenorphine—Dizziness—Etoposide—testicular cancer	0.000131	0.000764	CcSEcCtD
Buprenorphine—Muscle spasms—Epirubicin—testicular cancer	0.00013	0.000763	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—testicular cancer	0.00013	0.000762	CcSEcCtD
Buprenorphine—Vertigo—Methotrexate—testicular cancer	0.00013	0.000762	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—testicular cancer	0.00013	0.00076	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—testicular cancer	0.000129	0.000757	CcSEcCtD
Buprenorphine—Nausea—Cisplatin—testicular cancer	0.000128	0.000749	CcSEcCtD
Buprenorphine—Vision blurred—Epirubicin—testicular cancer	0.000128	0.000748	CcSEcCtD
Buprenorphine—Cough—Methotrexate—testicular cancer	0.000127	0.00074	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—testicular cancer	0.000126	0.000739	CcSEcCtD
Buprenorphine—Ill-defined disorder—Epirubicin—testicular cancer	0.000126	0.000737	CcSEcCtD
Buprenorphine—Convulsion—Methotrexate—testicular cancer	0.000126	0.000735	CcSEcCtD
Buprenorphine—Vomiting—Etoposide—testicular cancer	0.000126	0.000735	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—testicular cancer	0.000126	0.000734	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—testicular cancer	0.000126	0.000734	CcSEcCtD
Buprenorphine—Agitation—Epirubicin—testicular cancer	0.000125	0.000729	CcSEcCtD
Buprenorphine—Rash—Etoposide—testicular cancer	0.000125	0.000729	CcSEcCtD
Buprenorphine—Dermatitis—Etoposide—testicular cancer	0.000124	0.000728	CcSEcCtD
Buprenorphine—Headache—Etoposide—testicular cancer	0.000124	0.000724	CcSEcCtD
Buprenorphine—Flatulence—Doxorubicin—testicular cancer	0.000124	0.000724	CcSEcCtD
Buprenorphine—Chest pain—Methotrexate—testicular cancer	0.000123	0.000722	CcSEcCtD
Buprenorphine—Myalgia—Methotrexate—testicular cancer	0.000123	0.000722	CcSEcCtD
Buprenorphine—Arthralgia—Methotrexate—testicular cancer	0.000123	0.000722	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—testicular cancer	0.000123	0.000721	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—testicular cancer	0.000123	0.000719	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000123	0.000717	CcSEcCtD
Buprenorphine—Malaise—Epirubicin—testicular cancer	0.000122	0.000716	CcSEcCtD
Buprenorphine—Discomfort—Methotrexate—testicular cancer	0.000122	0.000713	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—testicular cancer	0.000122	0.000713	CcSEcCtD
Buprenorphine—Vertigo—Epirubicin—testicular cancer	0.000122	0.000713	CcSEcCtD
Buprenorphine—Syncope—Epirubicin—testicular cancer	0.000122	0.000712	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—testicular cancer	0.000121	0.00071	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—testicular cancer	0.000121	0.000706	CcSEcCtD
Buprenorphine—Palpitations—Epirubicin—testicular cancer	0.00012	0.000701	CcSEcCtD
Buprenorphine—Confusional state—Methotrexate—testicular cancer	0.000119	0.000698	CcSEcCtD
Buprenorphine—Loss of consciousness—Epirubicin—testicular cancer	0.000119	0.000698	CcSEcCtD
Buprenorphine—Cough—Epirubicin—testicular cancer	0.000118	0.000693	CcSEcCtD
Buprenorphine—Anaphylactic shock—Methotrexate—testicular cancer	0.000118	0.000692	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—testicular cancer	0.000118	0.000692	CcSEcCtD
Buprenorphine—Convulsion—Epirubicin—testicular cancer	0.000118	0.000688	CcSEcCtD
Buprenorphine—Infection—Methotrexate—testicular cancer	0.000118	0.000688	CcSEcCtD
Buprenorphine—Nausea—Etoposide—testicular cancer	0.000117	0.000686	CcSEcCtD
Buprenorphine—Hypertension—Epirubicin—testicular cancer	0.000117	0.000685	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—testicular cancer	0.000117	0.000681	CcSEcCtD
Buprenorphine—Nervous system disorder—Methotrexate—testicular cancer	0.000116	0.000679	CcSEcCtD
Buprenorphine—Chest pain—Epirubicin—testicular cancer	0.000116	0.000676	CcSEcCtD
Buprenorphine—Myalgia—Epirubicin—testicular cancer	0.000116	0.000676	CcSEcCtD
Buprenorphine—Arthralgia—Epirubicin—testicular cancer	0.000116	0.000676	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—testicular cancer	0.000115	0.000675	CcSEcCtD
Buprenorphine—Anxiety—Epirubicin—testicular cancer	0.000115	0.000673	CcSEcCtD
Buprenorphine—Skin disorder—Methotrexate—testicular cancer	0.000115	0.000672	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000115	0.000671	CcSEcCtD
Buprenorphine—Hyperhidrosis—Methotrexate—testicular cancer	0.000114	0.000669	CcSEcCtD
Buprenorphine—Discomfort—Epirubicin—testicular cancer	0.000114	0.000668	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—testicular cancer	0.000113	0.000662	CcSEcCtD
Buprenorphine—Dry mouth—Epirubicin—testicular cancer	0.000113	0.000661	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—testicular cancer	0.000113	0.00066	CcSEcCtD
Buprenorphine—Anorexia—Methotrexate—testicular cancer	0.000113	0.00066	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—testicular cancer	0.000113	0.000659	CcSEcCtD
Buprenorphine—Confusional state—Epirubicin—testicular cancer	0.000112	0.000653	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—testicular cancer	0.000111	0.000649	CcSEcCtD
Buprenorphine—Oedema—Epirubicin—testicular cancer	0.000111	0.000648	CcSEcCtD
Buprenorphine—Anaphylactic shock—Epirubicin—testicular cancer	0.000111	0.000648	CcSEcCtD
Buprenorphine—Hypotension—Methotrexate—testicular cancer	0.000111	0.000647	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—testicular cancer	0.00011	0.000646	CcSEcCtD
Buprenorphine—Infection—Epirubicin—testicular cancer	0.00011	0.000644	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—testicular cancer	0.00011	0.000641	CcSEcCtD
Buprenorphine—Shock—Epirubicin—testicular cancer	0.000109	0.000637	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—testicular cancer	0.000109	0.000636	CcSEcCtD
Buprenorphine—Nervous system disorder—Epirubicin—testicular cancer	0.000109	0.000635	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—testicular cancer	0.000108	0.000634	CcSEcCtD
Buprenorphine—Tachycardia—Epirubicin—testicular cancer	0.000108	0.000632	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000108	0.000631	CcSEcCtD
Buprenorphine—Skin disorder—Epirubicin—testicular cancer	0.000108	0.000629	CcSEcCtD
Buprenorphine—Hyperhidrosis—Epirubicin—testicular cancer	0.000107	0.000626	CcSEcCtD
Buprenorphine—Insomnia—Methotrexate—testicular cancer	0.000107	0.000626	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—testicular cancer	0.000107	0.000625	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—testicular cancer	0.000107	0.000625	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—testicular cancer	0.000107	0.000625	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—testicular cancer	0.000107	0.000623	CcSEcCtD
Buprenorphine—Paraesthesia—Methotrexate—testicular cancer	0.000106	0.000622	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000106	0.000621	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—testicular cancer	0.000106	0.000618	CcSEcCtD
Buprenorphine—Anorexia—Epirubicin—testicular cancer	0.000106	0.000618	CcSEcCtD
Buprenorphine—Dyspnoea—Methotrexate—testicular cancer	0.000106	0.000617	CcSEcCtD
Buprenorphine—Somnolence—Methotrexate—testicular cancer	0.000105	0.000615	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—testicular cancer	0.000105	0.000612	CcSEcCtD
Buprenorphine—Dyspepsia—Methotrexate—testicular cancer	0.000104	0.000609	CcSEcCtD
Buprenorphine—Hypotension—Epirubicin—testicular cancer	0.000103	0.000605	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—testicular cancer	0.000103	0.000604	CcSEcCtD
Buprenorphine—Decreased appetite—Methotrexate—testicular cancer	0.000103	0.000602	CcSEcCtD
Buprenorphine—Oedema—Doxorubicin—testicular cancer	0.000102	0.000599	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000102	0.000599	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000102	0.000598	CcSEcCtD
Buprenorphine—Fatigue—Methotrexate—testicular cancer	0.000102	0.000597	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—testicular cancer	0.000102	0.000596	CcSEcCtD
Buprenorphine—Pain—Methotrexate—testicular cancer	0.000101	0.000592	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000101	0.00059	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—testicular cancer	0.000101	0.00059	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—testicular cancer	0.0001	0.000588	CcSEcCtD
Buprenorphine—Insomnia—Epirubicin—testicular cancer	0.0001	0.000586	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—testicular cancer	0.0001	0.000585	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—testicular cancer	9.95e-05	0.000582	CcSEcCtD
Buprenorphine—Paraesthesia—Epirubicin—testicular cancer	9.94e-05	0.000582	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—testicular cancer	9.91e-05	0.000579	CcSEcCtD
Buprenorphine—Dyspnoea—Epirubicin—testicular cancer	9.87e-05	0.000578	CcSEcCtD
Buprenorphine—Somnolence—Epirubicin—testicular cancer	9.85e-05	0.000576	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—testicular cancer	9.77e-05	0.000571	CcSEcCtD
Buprenorphine—Feeling abnormal—Methotrexate—testicular cancer	9.75e-05	0.00057	CcSEcCtD
Buprenorphine—Dyspepsia—Epirubicin—testicular cancer	9.75e-05	0.00057	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Methotrexate—testicular cancer	9.68e-05	0.000566	CcSEcCtD
Buprenorphine—Decreased appetite—Epirubicin—testicular cancer	9.63e-05	0.000563	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—testicular cancer	9.58e-05	0.00056	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Epirubicin—testicular cancer	9.56e-05	0.000559	CcSEcCtD
Buprenorphine—Fatigue—Epirubicin—testicular cancer	9.55e-05	0.000559	CcSEcCtD
Buprenorphine—Pain—Epirubicin—testicular cancer	9.47e-05	0.000554	CcSEcCtD
Buprenorphine—Constipation—Epirubicin—testicular cancer	9.47e-05	0.000554	CcSEcCtD
Buprenorphine—Urticaria—Methotrexate—testicular cancer	9.4e-05	0.00055	CcSEcCtD
Buprenorphine—Abdominal pain—Methotrexate—testicular cancer	9.36e-05	0.000547	CcSEcCtD
Buprenorphine—Body temperature increased—Methotrexate—testicular cancer	9.36e-05	0.000547	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	9.34e-05	0.000546	CcSEcCtD
Buprenorphine—Insomnia—Doxorubicin—testicular cancer	9.27e-05	0.000542	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—testicular cancer	9.2e-05	0.000538	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—testicular cancer	9.14e-05	0.000534	CcSEcCtD
Buprenorphine—Feeling abnormal—Epirubicin—testicular cancer	9.13e-05	0.000534	CcSEcCtD
Buprenorphine—Somnolence—Doxorubicin—testicular cancer	9.11e-05	0.000533	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Epirubicin—testicular cancer	9.06e-05	0.00053	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—testicular cancer	9.02e-05	0.000528	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—testicular cancer	8.91e-05	0.000521	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—testicular cancer	8.85e-05	0.000518	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—testicular cancer	8.83e-05	0.000517	CcSEcCtD
Buprenorphine—Urticaria—Epirubicin—testicular cancer	8.8e-05	0.000515	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—testicular cancer	8.76e-05	0.000513	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—testicular cancer	8.76e-05	0.000513	CcSEcCtD
Buprenorphine—Body temperature increased—Epirubicin—testicular cancer	8.76e-05	0.000512	CcSEcCtD
Buprenorphine—Abdominal pain—Epirubicin—testicular cancer	8.76e-05	0.000512	CcSEcCtD
Buprenorphine—Hypersensitivity—Methotrexate—testicular cancer	8.72e-05	0.00051	CcSEcCtD
Buprenorphine—Asthenia—Methotrexate—testicular cancer	8.49e-05	0.000497	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—testicular cancer	8.44e-05	0.000494	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—testicular cancer	8.38e-05	0.00049	CcSEcCtD
Buprenorphine—Pruritus—Methotrexate—testicular cancer	8.37e-05	0.00049	CcSEcCtD
Buprenorphine—Hypersensitivity—Epirubicin—testicular cancer	8.16e-05	0.000477	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—testicular cancer	8.14e-05	0.000476	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—testicular cancer	8.1e-05	0.000474	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—testicular cancer	8.1e-05	0.000474	CcSEcCtD
Buprenorphine—Diarrhoea—Methotrexate—testicular cancer	8.1e-05	0.000474	CcSEcCtD
Buprenorphine—Asthenia—Epirubicin—testicular cancer	7.95e-05	0.000465	CcSEcCtD
Buprenorphine—Pruritus—Epirubicin—testicular cancer	7.84e-05	0.000458	CcSEcCtD
Buprenorphine—Dizziness—Methotrexate—testicular cancer	7.83e-05	0.000458	CcSEcCtD
Buprenorphine—Diarrhoea—Epirubicin—testicular cancer	7.58e-05	0.000443	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—testicular cancer	7.55e-05	0.000442	CcSEcCtD
Buprenorphine—Vomiting—Methotrexate—testicular cancer	7.52e-05	0.00044	CcSEcCtD
Buprenorphine—Rash—Methotrexate—testicular cancer	7.46e-05	0.000436	CcSEcCtD
Buprenorphine—Dermatitis—Methotrexate—testicular cancer	7.45e-05	0.000436	CcSEcCtD
Buprenorphine—Headache—Methotrexate—testicular cancer	7.41e-05	0.000434	CcSEcCtD
Buprenorphine—Asthenia—Doxorubicin—testicular cancer	7.35e-05	0.00043	CcSEcCtD
Buprenorphine—Dizziness—Epirubicin—testicular cancer	7.32e-05	0.000428	CcSEcCtD
Buprenorphine—Pruritus—Doxorubicin—testicular cancer	7.25e-05	0.000424	CcSEcCtD
Buprenorphine—Vomiting—Epirubicin—testicular cancer	7.04e-05	0.000412	CcSEcCtD
Buprenorphine—Nausea—Methotrexate—testicular cancer	7.03e-05	0.000411	CcSEcCtD
Buprenorphine—Diarrhoea—Doxorubicin—testicular cancer	7.01e-05	0.00041	CcSEcCtD
Buprenorphine—Rash—Epirubicin—testicular cancer	6.98e-05	0.000408	CcSEcCtD
Buprenorphine—Dermatitis—Epirubicin—testicular cancer	6.98e-05	0.000408	CcSEcCtD
Buprenorphine—Headache—Epirubicin—testicular cancer	6.94e-05	0.000406	CcSEcCtD
Buprenorphine—Dizziness—Doxorubicin—testicular cancer	6.78e-05	0.000396	CcSEcCtD
Buprenorphine—Nausea—Epirubicin—testicular cancer	6.58e-05	0.000385	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—testicular cancer	6.52e-05	0.000381	CcSEcCtD
Buprenorphine—Rash—Doxorubicin—testicular cancer	6.46e-05	0.000378	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—testicular cancer	6.46e-05	0.000378	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—testicular cancer	6.42e-05	0.000376	CcSEcCtD
Buprenorphine—Nausea—Doxorubicin—testicular cancer	6.09e-05	0.000356	CcSEcCtD
